Test Price
2,800 AED✅ Home Collection Available
ZFPM2 Gene Diaphragmatic Hernia Type 3 Genetic Test in UAE | 2800 AED | DHA Licensed Facility
Executive Summary & Core Metrics
Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189‑accredited NGS and Sanger confirmation processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily from 8 AM to 11 PM across all Emirates).
- Clinical Guidance: Post‑test telephonic result interpretation by DHA‑licensed genetic specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ZFPM2 Gene Diaphragmatic Hernia Type 3 Genetic Test identifies pathogenic variants in the ZFPM2 gene responsible for congenital diaphragmatic hernia (CDH) type 3, a severe birth defect affecting cardiovascular and pulmonary development. This ISO‑certified, DHA‑guided test delivers clinical‑grade results for confident decision‑making in UAE families.
The test employs Next‑Generation Sequencing (NGS) with full gene coverage, complemented by orthogonal Sanger confirmation, ensuring analytic sensitivity of 99.9%. Results are typically available within 3–4 weeks.
| Feature | Our ZFPM2 NGS Test | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (NGS) with full gene coverage & orthogonal Sanger confirmation | Sanger sequencing of limited exons |
| Analytic Sensitivity | 99.9% (ISO 15189 validated) | ~95% (varies by laboratory) |
| Turnaround Time | 3–4 Weeks | 5–6 Weeks |
| Price | 2,800 AED | 4,000–4,500 AED (often with add‑ons) |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh, DHA Registration ID: 9294403: “As a Consultant Medical Genetics, I emphasize that this test provides molecular confirmation for families facing congenital diaphragmatic hernia type 3. It does not replace comprehensive fetal ultrasound or postnatal cardiopulmonary assessment, but it offers critical information for recurrence risk counseling and prenatal planning. Please continue all prescribed medications and follow your obstetric or pediatric specialist’s guidance; do not discontinue any therapy without a qualified medical consultation.”
Advisory Notice
⚠️ Do not discontinue prescribed medication without consulting your doctor. This genetic test is elective and must be scheduled in consultation with your primary healthcare provider.
Patient Exclusion Criteria & Emergency Red Flags
Patient Safety & Exclusion Criteria
- Not suitable if the patient has received an allogeneic blood transfusion or stem cell transplant within the last 4 weeks (donor DNA may interfere).
- Individuals with acute decompensation, severe respiratory distress, or cyanosis should go directly to the emergency department; this genetic test is elective and must not delay urgent care.
- Emergency Red Flags: Sudden bluish skin, labored breathing, or marked chest retractions require immediate hospital evaluation—do not delay seeking care for a genetic test.
Patient FAQ & Clinical Guidance
1. What is the purpose of the ZFPM2 gene test for diaphragmatic hernia type 3?
Snippet: This NGS identifies pathogenic mutations in the ZFPM2 gene to confirm the genetic cause of congenital diaphragmatic hernia (CDH) type 3, guiding prognosis and family recurrence risk. The test helps families and clinicians decide on prenatal planning and postnatal management.
2. How is the sample collected and what are the logistics in the UAE?
Snippet: A simple blood draw, buccal swab, or dried blood spot on an FTA card is collected via VIP mobile phlebotomy with temperature‑controlled cold‑chain handling. Service is available daily from 8 AM to 11 PM across all Emirates. No hospital visit required for this standard sample type.
3. What are the implications for my child’s cardiac and respiratory health?
Snippet: ZFPM2 mutations often correlate with severe pulmonary hypoplasia and heart defects; early detection enables coordinated care with pediatric cardiology and surgery teams, reducing complications and improving long‑term outcomes.
UAE Regulatory & Data Privacy Adherence
This test is conducted under the regulatory framework of the Dubai Health Authority (DHA) and complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic data is encrypted, stored in UAE‑based servers, and never shared without explicit written consent.
Clinical & Logistical Metadata
| Test Name | ZFPM2 Gene Diaphragmatic Hernia Type 3 Genetic Test (NGS + Sanger Confirmation) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA), buccal swab, or dried blood spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) with full gene coverage + orthogonal Sanger confirmatory sequencing |
| ICD-10-CM Code | Q79.0 (Congenital diaphragmatic hernia) |
| LOINC Code | 82939-0 (ZFPM2 gene full mutation analysis by NGS) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians